Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
3(50%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
2
33%
Ph phase_3
1
17%
Ph phase_1
3
50%

Phase Distribution

3

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 2Efficacy & side effects
2(33.3%)
Phase 3Large-scale testing
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

6

all time

Status Distribution
Active(4)
Completed(2)

Detailed Status

Completed2
Active, not recruiting2
Recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
3
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (50.0%)
Phase 22 (33.3%)
Phase 31 (16.7%)

Trials by Status

completed233%
recruiting117%
active_not_recruiting233%
not_yet_recruiting117%

Recent Activity

3 active trials
Showing 5 of 6
active_not_recruitingphase_1

Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody

NCT05994001
active_not_recruitingphase_3

LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.

NCT06351020
recruitingphase_2

A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study

NCT05934331
not_yet_recruitingphase_2

Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic Cancer

NCT07108504
completedphase_1

Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors

NCT05188664
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT05994001Phase 1

Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody

Active Not Recruiting
NCT06351020Phase 3

LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.

Active Not Recruiting
NCT05934331Phase 2

A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study

Recruiting
NCT07108504Phase 2

Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic Cancer

Not Yet Recruiting
NCT05188664Phase 1

Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Completed
NCT05001516Phase 1

Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6